Skip to main navigation

Skip to content

Side Menu

About Us
Our Platform
Our Programs
Patients and Physicians
Inside Seres
Investors and News
Contact Us

Press Releases

Seres' news, events and other information can be found throughout the pages below.

Investor Relations

Stock Information
News and Events
- Press Releases
- Events & Presentations
Financial Information
- SEC Filings
- Annual Reports
Corporate Governance
Shareholder Services

Press Releases

Keyword Search

Year

Sep 22, 2020

Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit

Sep 14, 2020

Seres Therapeutics to Present at Upcoming Investor Conferences

Sep 11, 2020

Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results

Aug 17, 2020

Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock

Aug 12, 2020

Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock

Aug 11, 2020

Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Aug 10, 2020

Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection

Jul 28, 2020

Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates

Jun 22, 2020

Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer

Jun 02, 2020

Seres Therapeutics to Present at the Goldman Sachs 41st Annual Global Virtual Healthcare Conference

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Shareholder Tools

RSS Feeds
E-mail Alerts
Print

© 2020 Seres Therapeutics.

Footer Left Menu

Privacy Policy
Terms of Use

Follow us on Linkedin
Follow us on Twitter
Follow us on Facebook